Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

KPTI

Insider Sentiment (TTM):

Last Purchase:2023-09-12Last Sale:2026-05-14Shares Purchased (TTM):0Shares Sold (TTM):40,664

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:15,681,012Shares Outstanding:22,014,000Institutional Ownership Pct.:71.23%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	55	91	61	38	39	39	62	73	85	31	52	44
Available For Sale Securities Debt Securities Curr…	10	0	3	8	13	31	46	61	67	118	139	165
Receivables Net Current	30	23	26	32	33	35	31	32	38	31	27	38
Inventory Net	4	4	4	4	5	5	5	5	3	3	3	3
Prepaid Expense And Other Assets Current	7	9	9	8	8	10	12	15	15	15	12	13
Restricted Cash And Cash Equivalents At Carrying V…	-	-	0	-	-	-	0	0	0	0	1	1
Assets Current	106	126	103	90	98	120	156	185	209	198	234	263
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	1	1	1	1
Operating Lease Right Of Use Asset	4	4	5	5	5	5	6	3	3	4	4	5
Restricted Cash And Cash Equivalents Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	0	0	1	1	1	1	1	1	1	1	1
Assets	111	131	108	96	105	128	164	189	214	204	240	270
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	8	4	4	5	3	6	5	6	3	5	3	1
Accrued Liabilities Current	79	76	64	66	63	57	61	50	50	55	61	56
Secured Debt Current	40	32	21	13	6	-	0	-	-	-	-	-
Operating Lease Liability Current	1	1	1	1	1	1	0	4	4	3	3	3
Other Liabilities Current	6	3	2	2	2	2	2	2	1	2	2	2
Liabilities Current	134	117	92	87	99	90	92	61	58	65	69	62
Convertible Long Term Notes Payable	-	-	-	-	-	-	0	-	-	171	171	171
Secured Long Term Debt	85	88	95	84	90	95	95	94	94	-	0	-
Operating Lease Liability Noncurrent	5	5	6	6	6	6	7	0	1	2	3	4
Other Liabilities Noncurrent	0	0	11	14	8	5	2	6	4	3	1	1
Liabilities	441	397	401	365	344	334	350	349	346	373	377	370
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,519	1,516	1,466	1,388	1,385	1,381	1,378	1,373	1,369	1,356	1,351	1,346
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	-0	-0	-0	-0	-0	-1	-1	-0	-1
Retained Earnings Accumulated Deficit	-1,849	-1,782	-1,759	-1,657	-1,624	-1,587	-1,563	-1,533	-1,501	-1,524	-1,487	-1,445
Stockholders Equity	-330	-266	-293	-269	-239	-206	-186	-160	-132	-169	-136	-100
Liabilities And Stockholders Equity	111	131	108	96	105	128	164	189	214	204	240	270
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	106	106	53	53	53	53	53	400	400	400	400	400
Common Stock Shares Issued	23	23	18	9	9	9	8	8	8	8	8	8
Shares Outstanding	23	23	18	9	9	9	8	8	8	8	8	8

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	2.02%	7.87%	-78.43%	-	-	-	-	-	-	-	-	-
2025	-26.99%	-28.62%	-36.10%	75.07%	69.23%	53.85%	-7.41%	22.57%	8.57%	2.21%	-31.35%	2.21%
2024	-5.00%	-14.90%	-4.80%	-9.52%	-13.81%	-1.55%	-0.12%	-17.14%	-17.26%	-25.00%	-52.33%	-33.22%
2023	-	-	-	-	-	-	-3.02%	8.28%	0.66%	19.83%	0.86%	-0.86%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	0.79	1.08	1.12	1.03	0.99	1.33	1.70	3.00	3.62	3.04	3.37	4.24
Quick Ratio	0.71	0.97	0.98	0.89	0.85	1.16	1.51	2.69	3.30	2.76	3.15	3.98
Working Capital	-27.86M	9.03M	11.09M	2.59M	-1.35M	29.87M	64.20M	123.26M	150.92M	133.03M	164.44M	201.14M
Leverage & Debt
Debt to Equity	-1.34	-1.49	-1.37	-1.36	-1.44	-1.62	-1.88	-2.19	-2.62	-2.21	-2.77	-3.69
Interest Coverage TTM	-2.49	-2.02	-1.98	-2.34	-2.57	-2.80	-3.19	-3.88	-4.83	-5.53	-5.44	-5.34
Debt Ratio	3.97	3.02	3.70	3.80	3.28	2.61	2.13	1.84	1.62	1.83	1.57	1.37
Efficiency & Turnover
Asset Turnover TTM	1.36	1.17	1.07	1.00	0.86	0.86	0.72	0.65	0.57	0.53	0.49	0.58
Days Sales Outstanding TTM	78.17	70.77	71.15	81.51	94.30	85.17	72.54	85.69	88.04	86.12	92.54	81.79
Receivables Turnover TTM	4.67	5.16	5.13	4.48	3.87	4.29	5.03	4.26	4.15	4.24	3.94	4.46
Per Share Metrics
Diluted EPS TTM	-7.77	-7.89	-17.93	-14.38	-14.33	-7.38	-9.04	-10.49	-8.73	-19.00	-18.78	-18.32
Free Cash Flow Per Share TTM	-2.26	-2.69	-6.89	-10.31	-11.95	-14.50	-15.72	-14.45	-16.18	-15.29	-12.17	-13.23
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	-	96.03%	95.93%	95.93%	96.37%	96.20%	95.86%	95.85%	96.04%	96.08%	96.62%	96.35%
Operating Profit Margin TTM	-56.17%	-55.73%	-62.10%	-73.07%	-83.93%	-83.69%	-82.24%	-84.86%	-89.89%	-94.26%	-88.71%	-86.11%
Net Profit Margin TTM	-153.28%	-129.02%	-134.21%	-87.43%	-90.02%	-43.99%	-52.62%	-58.93%	-61.72%	-104.18%	-97.99%	-95.82%
Growth Metrics
Net Revenue Growth (1Y)	6.81%	6.33%	0.57%	-3.98%	-5.77%	1.19%	-0.55%	1.77%	-0.23%	-5.16%	-7.03%	-41.60%
Net Income Growth (1Y)	81.88%	211.84%	156.52%	42.46%	37.43%	-57.27%	-46.60%	-37.41%	-36.50%	-7.39%	-13.43%	58.71%
EPS Growth (1Y)	-45.82%	19.98%	90.60%	36.99%	28.64%	-61.16%	-49.92%	-42.71%	-40.05%	-8.97%	-37.95%	11.28%
Valuation Metrics
P/E TTM	-1.26	-0.63	-0.41	-0.45	-0.30	-0.51	-1.08	-1.19	-1.17	-1.19	-0.69	-1.10
P/B TTM	-0.86	-0.46	-0.27	-0.21	-0.16	-0.15	-0.44	-0.65	-0.80	-1.03	-0.73	-1.53
P/S TTM	1.93	0.81	0.55	0.40	0.27	0.22	0.57	0.70	0.72	1.24	0.68	1.05
Market Cap	282.72M	122.62M	80.48M	56.70M	37.15M	31.68M	82.39M	103.78M	105.06M	174.40M	98.85M	153.37M
Enterprise Value	352.78M	151.93M	135.40M	115.07M	93.89M	87.75M	114.51M	124.73M	113.47M	314.14M	216.58M	279.49M
Calculated Values
Free Cash Flow TTM	-65.35M	-59.11M	-75.37M	-89.40M	-103.00M	-122.80M	-127.73M	-120.46M	-130.53M	-117.73M	-92.72M	-100.98M
Net Debt	70.06M	29.31M	54.91M	58.37M	56.74M	56.07M	32.13M	20.94M	8.41M	139.74M	117.73M	126.12M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-14Sale

Owner: Poulton, Stuart

Title: EVP, Chief Development Officer

Shares: 403

Price/Share: $9.50

Value: $3,828.50

Shares Owned: 94,821

Relationship: Officer

Ownership: Direct

2026-05-14Sale

Owner: Rangwala, Reshma

Title: EVP & Chief Medical Officer

Shares: 408

Price/Share: $9.50

Value: $3,876.00

Shares Owned: 56,829

Relationship: Officer

Ownership: Direct

2026-05-14Sale

Owner: Mano, Michael

Title: EVP, CLO&Secretary

Shares: 266

Price/Share: $9.50

Value: $2,527.00

Shares Owned: 94,398

Relationship: Officer

Ownership: Direct

2026-05-14Sale

Owner: Paulson, Richard A.

Title: President and CEO

Shares: 2,203

Price/Share: $9.50

Value: $20,928.50

Shares Owned: 269,747

Relationship: Director,Officer

Ownership: Direct

2026-05-14Sale

Owner: Abate, Kristin

Title: Chief Accounting Officer

Shares: 53

Price/Share: $9.50

Value: $503.50

Shares Owned: 23,801

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-14	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	403	9.50	$3,828.50	94,821	4
2026-05-14	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	408	9.50	$3,876.00	56,829	4
2026-05-14	Mano, Michael	Officer	EVP, CLO&Secretary	Direct	Sale	266	9.50	$2,527.00	94,398	4
2026-05-14	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	2,203	9.50	$20,928.50	269,747	4
2026-05-14	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	53	9.50	$503.50	23,801	4
2026-05-14	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	324	9.50	$3,078.00	107,940	4
2026-04-21	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	449	8.94	$4,014.06	56,290	4
2026-03-02	Mano, Michael	Officer	EVP, CLO&Secretary	Direct	Sale	3,526	9.41	$33,179.66	93,964	4
2026-03-02	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	4,604	9.41	$43,323.64	107,317	4
2026-03-02	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	5,101	9.41	$48,000.41	94,328	4
2026-03-02	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	5,066	9.41	$47,671.06	56,739	4
2026-03-02	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	559	9.41	$5,260.19	22,063	4
2026-03-02	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	12,361	9.41	$116,317.01	267,030	4
2026-02-17	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	378	8.63	$3,262.14	99,429	4
2026-02-03	Macomber, Lori	Officer	EVP, CFO & Treasurer	Direct	Sale	1,626	6.30	$10,243.80	85,105	4
2026-01-28	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	50	7.03	$351.50	22,622	4
2026-01-21	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	265	5.96	$1,579.40	22,580	4
2025-10-01	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	362	6.30	$2,280.60	10,046	4
2025-09-15	Mano, Michael	Officer	SVP, General Counsel&Secretary	Direct	Sale	234	6.43	$1,504.62	21,425	4
2025-09-15	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	401	6.43	$2,578.43	27,710	4
2025-09-15	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	408	6.43	$2,623.44	29,390	4
2025-09-15	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	23	6.43	$147.89	10,408	4
2025-09-15	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	1,257	6.43	$8,082.51	84,046	4
2025-09-15	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	325	6.43	$2,089.75	35,856	4
2025-09-03	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	12	6.78	$81.36	9,463	4
2025-07-29	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	191	4.37	$834.67	27,223	4
2025-07-22	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	238	4.00	$952.00	9,475	4
2025-05-06	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	236	7.12	$1,680.32	82,503	4
2025-04-23	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	419	6.17	$2,585.23	28,853	4
2025-04-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	245	3.74	$916.30	82,739	4
2025-03-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	11,694	6.29	$73,555.26	82,984	4
2025-03-04	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	3,548	6.29	$22,316.92	27,414	4
2025-03-04	Abate, Kristin	Officer	Chief Accounting Officer	Direct	Sale	571	6.29	$3,591.59	9,713	4
2025-03-04	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	3,445	6.29	$21,669.05	34,314	4
2025-03-04	Mano, Michael	Officer	SVP, General Counsel&Secretary	Direct	Sale	2,793	6.29	$17,567.97	21,047	4
2025-03-04	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	3,587	6.29	$22,562.23	29,272	4
2025-02-18	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	5,914	0.63	$3,725.82	320,714	4
2025-02-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	4,099	0.65	$2,664.35	1,120,158	4
2025-01-06	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	4,055	0.78	$3,162.90	1,124,257	4
2024-12-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,620	0.81	$2,932.20	1,128,312	4
2024-11-05	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,675	0.91	$3,344.25	1,131,932	4
2024-10-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,607	0.88	$3,174.16	1,135,607	4
2024-09-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,667	0.72	$2,640.24	1,139,214	4
2024-09-04	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	5,356	0.72	$3,856.32	404,051	4
2024-09-04	Mano, Michael	Officer	SVP, General Counsel&Secretary	Direct	Sale	3,971	0.72	$2,859.12	273,881	4
2024-09-04	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	7,050	0.72	$5,076.00	391,054	4
2024-08-06	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,608	0.93	$3,355.44	1,142,881	4
2024-07-30	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	2,883	1.06	$3,055.98	326,628	4
2024-07-05	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,616	0.85	$3,073.60	1,146,489	4
2024-06-07	Pakianathan, Deepika	Director	-	Indirect	Sale	231,548	0.95	$219,970.60	0	4
2024-06-04	Pakianathan, Deepika	Director	-	Indirect	Sale	341,040	0.95	$323,988.00	7,911	4
2024-06-04	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	652	0.99	$645.48	398,104	4
2024-06-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,592	0.99	$3,556.08	1,150,105	4
2024-05-06	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,576	1.13	$4,040.88	1,153,697	4
2024-04-22	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	6,789	1.17	$7,943.13	342,931	4
2024-04-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,563	1.29	$4,596.27	1,157,273	4
2024-03-05	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,573	1.30	$4,644.90	1,160,836	4
2024-03-01	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	6,155	1.20	$7,386.00	329,511	4
2024-03-01	Rangwala, Reshma	Officer	EVP & Chief Medical Officer	Direct	Sale	5,969	1.20	$7,162.80	349,720	4
2024-03-01	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	5,109	1.20	$6,130.80	393,509	4
2024-03-01	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	19,374	1.20	$23,248.80	1,164,409	4
2024-03-01	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	6,162	1.20	$7,394.40	398,756	4
2024-03-01	Mano, Michael	Officer	SVP, General Counsel&Secretary	Direct	Sale	3,576	1.20	$4,291.20	277,852	4
2024-02-27	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	2,545	1.32	$3,359.40	244,400	4
2024-02-15	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	5,847	1.36	$7,951.92	163,772	4
2024-02-06	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	4,012	1.59	$6,379.08	821,453	4
2024-02-06	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	4,205	1.59	$6,685.95	246,945	4
2024-01-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	4,114	0.82	$3,373.48	783,465	4
2023-12-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,622	0.79	$2,861.38	787,579	4
2023-11-06	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,606	0.92	$3,317.52	791,201	4
2023-10-04	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,589	1.27	$4,558.03	794,807	4
2023-09-12	Bohlin, Garen G	Director	-	Direct	Purchase	41,140	1.22	$50,190.80	45,140	4
2023-09-05	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,622	1.33	$4,817.26	798,396	4
2023-09-01	Mano, Michael	Officer	SVP, General Counsel&Secretary	Direct	Sale	3,888	1.33	$5,171.04	142,234	4
2023-09-01	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	7,415	1.33	$9,861.95	204,086	4
2023-09-01	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	6,913	1.33	$9,194.29	237,817	4
2023-08-07	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,722	1.72	$6,401.84	802,018	4
2023-07-28	Poulton, Stuart	Officer	EVP, Chief Development Officer	Direct	Sale	2,845	1.70	$4,836.50	156,286	4
2023-07-05	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,538	1.72	$6,085.36	805,740	4
2023-06-08	Cheng, Sohanya Roshan	Officer	EVP & Chief Commercial Officer	Direct	Sale	1,839	2.35	$4,321.65	211,501	4
2023-06-05	Paulson, Richard A.	Director,Officer	President and CEO	Direct	Sale	3,536	2.24	$7,920.64	809,278	4
2023-06-02	Mason, Michael	Officer	EVP, CFO & Treasurer	Direct	Sale	631	2.22	$1,400.82	244,730	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

71.23%

Inst. Shares: 15,681,012

Shares Outstanding: 22,014,000

2025-12-31

71.77%

Inst. Shares: 7,847,932

Shares Outstanding: 10,935,000

2025-09-30

24.42%

Inst. Shares: 2,116,939

Shares Outstanding: 8,669,000

2025-06-30

40.81%

Inst. Shares: 3,518,239

Shares Outstanding: 8,620,000

2025-03-31

63.98%

Inst. Shares: 5,419,379

Shares Outstanding: 8,470,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	15,681,012	22,014,000	71.23%
2025-12-31	7,847,932	10,935,000	71.77%
2025-09-30	2,116,939	8,669,000	24.42%
2025-06-30	3,518,239	8,620,000	40.81%
2025-03-31	5,419,379	8,470,000	63.98%
2024-12-31	57,280,597	8,125,000	-
2024-09-30	55,502,828	8,336,000	-
2024-06-30	63,587,309	8,069,000	-
2024-03-31	69,898,326	7,700,000	-
2023-12-31	66,090,373	7,618,541	-
2023-09-30	70,595,743	7,630,547	-
2023-06-30	74,315,588	7,617,607	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Karyopharm Therapeutics Inc. (KPTI) — SEC Financial Statements & Analysis

Karyopharm Therapeutics Inc. (KPTI) is a pharmaceutical preparations company, incorporated in DE. Karyopharm Therapeutics Inc. trades on Nasdaq as: KPTI. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Karyopharm Therapeutics Inc. reported a 6.81% year-over-year revenue growth, a Gross Profit Margin of 96.03% (TTM), a Debt-to-Equity ratio of -1.34x, a Price-to-Sales (P/S) ratio of 1.93x (TTM), a Price-to-Book (P/B) ratio of -0.86x (TTM), at a market cap of $282.72M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 6.81%
Gross Profit Margin TTM: 96.03%
Debt To Equity: -1.34x
P/S TTM: 1.93x
P/B TTM: -0.86x
Market Cap: $282.72M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Karyopharm Therapeutics Inc. in?

Karyopharm Therapeutics Inc. (KPTI) operates in the Pharmaceutical Preparations industry.

What is KPTI's market cap?

Karyopharm Therapeutics Inc. (KPTI) has a market capitalization of $282.72M as of 2026-06-30.

What exchange does KPTI trade on?

Karyopharm Therapeutics Inc. (KPTI) trades on the Nasdaq.

Where is Karyopharm Therapeutics Inc. incorporated?

Karyopharm Therapeutics Inc. is incorporated in DE.